In addition to seeking potential partners for our internal pipeline we are currently seeking partnerships and collaborations for the following platform technologies:
Proof-of-concept research collaborations utilizing partner’s antibodies. We have developed a proprietary antibody-drug conjugate (ADC) linker called CL2A, designed for targeted delivery of SN-38. Click here to learn more.
Proof-of-concept research collaborations utilizing partner’s targets and/or antibodies. DOCK-AND-LOCK®, or DNL®, is a proprietary platform technology for creating a wide variety of multivalent antibodies of increasing complexity. Click here to learn more.
Non-exclusive licenses are available. We have invented a novel and facile method of labeling peptides with fluorine-18 (F-18) for use in imaging of diseases using position-emission tomography. Click here to learn more.